|Articles|January 1, 1998

A Managed Care Appraisal of Atypical Agents in the Treatment of Psychoses
Volume 4
Issue 1 Suppl

Introduction - The Routine Use of Atypical Antipsychotics

Download PDF: Introduction - The Routine Use of Atypical Antipsychotics

Articles in this issue

over 28 years ago

Article

Common Treatment Goals: Switching Antipsychotics

over 28 years ago

Article

Antipsychotics : Present and Future

over 28 years ago

Article

Atypical Antipsychotics in the Managed Care Era

over 28 years ago

Article

CME Quiz

over 28 years ago

Article

Selected Abstracts

over 28 years ago

Article

Bibliography

over 28 years ago

Article

Participating Faculty

over 28 years ago

Article

Atypical Antipsychotics and Formulary Decisions

over 28 years ago

Article

Chronic Ambulatory Outpatients and Four-Vector Management

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

Introduction - The Routine Use of Atypical Antipsychotics

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

An Interview With Lucio Gordan, MD: Community Oncology and CAR T-Cell Therapy

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Introduction - The Routine Use of Atypical Antipsychotics

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

An Interview With Lucio Gordan, MD: Community Oncology and CAR T-Cell Therapy